Skip to main content
Premium Trial:

Request an Annual Quote

Affy Stock Slides 13 Percent on Weak Q2 as Banks Downgrade Shares and Temper Outlook

NEW YORK (GenomeWeb News) – Shares in Affymetrix were down approximately 13 percent, or $2.72, at $18.85 in mid-afternoon trading today after the company yesterday posted a $10.1 million net loss and a 4.7-percent decline in revenue for the second quarter.
 
The stock is currently trading at levels not seen since 2003.
 
Separately today, investment bank Thomas Weisel downgraded the stock to “Peer Perform” from “Outperform,” saying the company’s earnings outlook lacked clarity. Also today, Infinium Securities downgraded the stock to “Underperform” from “Neutral.”
 
Additionally, Lehman Brothers and PiperJaffray lowered their price targets for the company, Lehman to $25 from $39 and PiperJaffray to $21 from $27, according to Marketwatch.com.
 
According to Marketwatch, J.P. Morgan analyst Tycho Peterson said: "Flummoxed by the continued spate of revenue and earnings disappointments, a tempered outlook and lack of any meaningful visibility around the timing and magnitude of a turnaround, we expect investors will remain hesitant to re-embrace [Affymetrix's] story.”

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.